JP2009537532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009537532A5 JP2009537532A5 JP2009511024A JP2009511024A JP2009537532A5 JP 2009537532 A5 JP2009537532 A5 JP 2009537532A5 JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009511024 A JP2009511024 A JP 2009511024A JP 2009537532 A5 JP2009537532 A5 JP 2009537532A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- hydrogen
- compound
- independently selected
- bromine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74722006P | 2006-05-15 | 2006-05-15 | |
| US84996806P | 2006-10-06 | 2006-10-06 | |
| PCT/US2007/011622 WO2007133772A2 (en) | 2006-05-15 | 2007-05-15 | Cdki pathway inhibitors as selective inhibitors of tumor cell growth |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009537532A JP2009537532A (ja) | 2009-10-29 |
| JP2009537532A5 true JP2009537532A5 (enExample) | 2012-09-20 |
Family
ID=38694543
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009511024A Pending JP2009537532A (ja) | 2006-05-15 | 2007-05-15 | 腫瘍細胞増殖の選択的阻害剤としてのｃｄｋｉ経路阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20080200531A1 (enExample) |
| EP (1) | EP2023925A4 (enExample) |
| JP (1) | JP2009537532A (enExample) |
| AU (1) | AU2007249761A1 (enExample) |
| CA (1) | CA2652339A1 (enExample) |
| WO (1) | WO2007133772A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103347517B (zh) | 2010-08-11 | 2018-10-02 | 德雷克塞尔大学 | 治疗帕金森病中运动障碍的d3多巴胺受体激动剂 |
| WO2013063492A1 (en) * | 2011-10-28 | 2013-05-02 | Board Of Regents, The University Of Texas System | Novel compositions and methods for treating cancer |
| CN103468786B (zh) * | 2012-06-06 | 2017-06-13 | 上海吉凯基因化学技术有限公司 | 人cdkl3基因的用途及其相关药物 |
| WO2014089450A1 (en) | 2012-12-06 | 2014-06-12 | Senex Biotechnology, Inc. | Specific inhibitors of cdk3 |
| US10584369B2 (en) * | 2013-01-11 | 2020-03-10 | Senex Biotechnology, Inc. | Cell-based methods for measuring activity of a protein inhibitor |
| CA2928429C (en) | 2013-10-28 | 2022-08-30 | Drexel University | Aminoalkyl phenyl derivatives useful in the treatment of adhd and other cognitive disorders |
| US11013728B2 (en) | 2017-04-03 | 2021-05-25 | Kyoto Pharmaceutical Industries, Ltd. | Cyclin-dependent kinase 8 and/or 19 inhibitor |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3915990A (en) * | 1973-03-13 | 1975-10-28 | Nelson Res & Dev | Tryptamines |
| US5849733A (en) * | 1996-05-10 | 1998-12-15 | Bristol-Myers Squibb Co. | 2-thio or 2-oxo flavopiridol analogs |
| ES2213996T3 (es) * | 1999-12-08 | 2004-09-01 | Centre National De La Recherche Scientifique (Cnrs) | Uso de himenialdisina o sus derivados en la fabricacion de medicamentos. |
| AU2004271730A1 (en) * | 2003-09-18 | 2005-03-24 | Novartis Ag | Combination of a histone deacetylase inhibitor with a death receptor ligand |
| JP2008540586A (ja) * | 2005-05-18 | 2008-11-20 | フォルシュングスフェアブント ベルリン エー ファウ | Ａｋａｐ−ｐｋａ相互作用の非ペプチド阻害剤 |
-
2007
- 2007-05-15 CA CA002652339A patent/CA2652339A1/en not_active Abandoned
- 2007-05-15 WO PCT/US2007/011622 patent/WO2007133772A2/en not_active Ceased
- 2007-05-15 JP JP2009511024A patent/JP2009537532A/ja active Pending
- 2007-05-15 EP EP07809083A patent/EP2023925A4/en not_active Withdrawn
- 2007-05-15 US US11/803,739 patent/US20080200531A1/en not_active Abandoned
- 2007-05-15 AU AU2007249761A patent/AU2007249761A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010526814A5 (enExample) | ||
| JP2008535902A5 (enExample) | ||
| JP2018535967A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2011504903A5 (enExample) | ||
| JP2015508103A5 (enExample) | ||
| JP2009515988A5 (enExample) | ||
| JP2014504646A5 (enExample) | ||
| NZ702914A (en) | Ite for cancer intervention and eradication | |
| JP2010502730A5 (enExample) | ||
| NZ610104A (en) | Polymorphic forms of 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4h-1,2,4-triazol-3-ylthio) acetic acid and uses thereof | |
| EP2620432A3 (en) | Diarylhydantoin compounds | |
| RU2009115179A (ru) | Кристаллические формы соединения тиазолидиндиона и способ его получения | |
| JP2011527666A5 (enExample) | ||
| JP2014510149A5 (enExample) | ||
| JP2012509265A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2012508274A5 (enExample) | ||
| BRPI0506765A (pt) | composto ou um seu sal, hidrato e/ou pró-droga farmaceuticamente aceitáveis, composição farmacêutica, métodos para inibir a produção de beta-amilóide em um paciente e para tratar de uma doença, kit farmacêutico, uso de um composto ou de uma composição | |
| JP2013500342A5 (enExample) | ||
| JP2018531987A5 (enExample) | ||
| JP2010527985A5 (enExample) | ||
| JP2006501201A5 (enExample) | ||
| TNSN08020A1 (en) | 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them | |
| JP2012507535A5 (enExample) |